print_label | resize_label

Technology Data

Spirogen’s Antibody-Drug Conjugate (ADC) technology delivers extremely potent anticancer agents to cancer cells by attaching them to antibodies.

We have developed highly potent warheads based on our proprietary PBDs. These PBD warheads are joined to antibodies by linkers which are stable in the bloodstream but release the PBD warhead once it is safely inside the targeted cancer cells.

Evident in our data, ADCs developed using PBDs demonstrate superior in vivo anti-tumor activity.

Spirogen ADC In Vivo Activity Compared to Competitors

TRASTUZUMAB ADCS IN HER2 +VE BT474 HUMAN BREAST CANCER MODEL

data top

PBD ADC at equivalent dose produces significantly better anti-tumor activity than auristatin and maytansinoid-based HER2 ADCs

Single-dose Anti-tumor Activity in MDR+ AML
(HEL92.1.7)

data middle


Durable growth delay with C2-Anilino PBD-ADC at 1 mg/kg

Single-dose Anti-tumor Activity in MDR+ AML
(TF1-A, SUBCUTANEOUS MODEL)

data bottom

No effect with gemtuzumab ozogamicin (Mylotarg) at 1 mg/kg

Good activity with C2-Anilino PBD-ADC at 0.3 mg/kg

SCID mice were implanted subcutaneously with HEL92.1.7, TF-α or HL-60 cells. Once tumors were ~100 mm3, a single dose of SGN-CD33A, non-binding control ADC, or gemtuzumab ozogamicin (GO) was administered (arrow). Source: Sutherland et al. (Seattle Genetics) 54th ASH Annual Meeting and Exposition, Atlanta, GA, December 8-12 2012; Sutherland et al. Blood, 122, 1455-16, 2013.

Activity in a small cell lung cancer (SCLC) patient-derived xenograft (PDX) tumor model.
(SCLC PDX model)

SCLC PDX MODEL


Complete responses to PBD-ADC SC16LD6.5 (Rovalpituzumab teserine) in a SCLC PDX model.

Source: Saunders LA et al Science Translational Medicine 2015 7(302):302ra136.

Clinical Experience with PBD-based ADCs

STEMCENTRX
  • Rovalpituzumab tesirine (SC16LD6.5; DLL-3 targeted ADC) in Small Cell Lung Cancer
SEATTLE GENETICS
  • SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
    Kung Sutherland MS, et al. Blood. 2013 Aug 22;122(8):1455-63.
  • SGN-CD70a in Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
ADC THERAPEUTICS
  • ADCT-301 in Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Acute Lymphoblastic Leukemia, Adult T-cell leukemia/lymphoma, Acute Myeloid Leukemia, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
data last